Tag: M.W:200-300

49679-45-0, Ethyl 3-chloroquinoxaline-2-carboxylate is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step J (Compound 10): [00150] Compound 6 (77.7 mg./0. 33 mmol. ) was dissolved in ethanol. Added was 3,5- Dimethyl aniline and the reaction mixture (in a sealed tube) was heated to 85 degrees. After stirring overnight, the reaction was allowed to cool to room temperature. The precipitated solid was diluted with ethanol and collected by filtration. Yield: 33.7 mg. approximately 30%. LC Data-retention time: 7.166 min. , >95% pure, MS+ (FIA) Data: 322.1., 49679-45-0

The synthetic route of 49679-45-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; VERTEX PHARMACEUTICALS INCORPORATED; WO2005/56547; (2005); A2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

6-Bromo quinoxaline (2.0 g, 9.5 mmol) in toluene (20 mL) was degassed for 30 min. To this solution, 1-ethoxy vinyl tributyltin (3.8 g, 10.5 mmol) and bis(triphenylphosphine)palladium dichloride (0.67 g, 0.95 mmol) were added at rt and stirred for 16 hours at 90 C. The reaction mixture was cooled to rt and filtered through celite. After evaporation of the solvent, 6 N HCI solution in water (20 mL) was added and the mixture was stirred for 1 hour at rt. It was concentrated and neutralized with sat. NaHCO3. The desired product was extracted with DCM (100 mL), dried over Na2SO4 and concentrated. The crude product was purified by column chromatography to afford the title compound (brown solid). 1H NMR (400 MHz, DMSO-de): delta 9.06-9.04 (m, 2H), 8.70 (d, J=2.4 Hz, 1 H), 8.28 (t, J = 2.8 Hz, 1 H), 8.16 (d, J = 11.6 Hz, 1 H), 2.97 (s, 3H). LCMS: (Method A) 173 (M+H), Rt. 2.25 min, 99.06% (Max).

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; ASCENEURON S. A.; QUATTROPANI, Anna; KULKARNI, Santosh, S.; GIRI, Awadut Gajendra; (247 pag.)WO2017/144639; (2017); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

49679-45-0, Ethyl 3-chloroquinoxaline-2-carboxylate is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,49679-45-0

To a mixture of ethyl 3-chloroquinoxaline-2-carboxylate (1 g,4.22 mmol) and 2-bromophenylboronic acid (0.93 g, 4.64mmol) in MeCN (30 mL), was added Pd(PPh3)4 (0.097 g, 0.084mmol) and 2 M aq Na2CO3 solution (10 mL). The resultingmixture was stirred at 100 C for 5 h. After cooling the mixturewas diluted with CH2Cl2 and washed three times with H2O anddried over MgSO4. After filtration and evaporation of the solvent,the crude product was purified by silica gel chromatographywith CH2Cl2 as eluent to furnish the product 3 as a yellowsolid; yield 1.1 g (73%); mp 100 C. 1H NMR (250 MHz, CDCl3): delta= 1.19 (t, J = 7.1 Hz, 3 H, CH3), 4.33 (q, J = 7.1 Hz, 2 H, CH2), 7.33-7.40 (m, 1 H, HAr), 7.45-7.85 (m, 2 H, HAr), 7.67 (d, J = 8.0 Hz, 1 H,HAr), 7.89-7.93 (m, 2 H, HAr), 8.19-8.23 (m, 1 H, HAr), 8.31-8.35(m, 1 H, HAr). 13C NMR (62.5 MHz, CDCl3): delta = 13.7, 62.3, 122.1,127.6, 129.3, 130.0, 130.3, 130.5, 131.0, 132.1, 132.3, 139.8,140.4, 142.0, 144.4, 153.2, 164.7. Anal. Calcd for C17H13BrN2O2:C, 57.16; H, 3.67; N, 7.84. Found: C, 57.61; H, 3.61; N, 7.86.

The synthetic route of 49679-45-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Khoumeri, Omar; Vanelle, Francois-Xavier; Crozet, Maxime D.; Terme, Thierry; Vanelle, Patrice; Synlett; vol. 27; 10; (2016); p. 1547 – 1550;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.49679-45-0,Ethyl 3-chloroquinoxaline-2-carboxylate,as a common compound, the synthetic route is as follows.,49679-45-0

A solution of ethyl 3-chloroquinoxaline-2-carboxylate (500 mg, 2.12 mmol) in morpholine (5 mL was stirred for 1 hour at 100C. It was diluted with water, extracted with EA (x3), washed with brine (x2). The organic layer was dried and concentrated to give 450 mg (crude) of desired compound as yellow oil, which was used directly in the next step without further purification. ESI MS m/z = 287.5 [M+H]+.

As the paragraph descriping shows that 49679-45-0 is playing an increasingly important role.

Reference£º
Patent; ENANTA PHARMACEUTICALS, INC.; SHOOK, Brian, C.; KIM, In, Jong; BLAISDELL, Thomas, P.; YU, Jianming; PANARESE, Joseph; LIN, Kai; RHODIN, Michael, H.J.; McALLISTER, Nicole, V.; OR, Yat, Sun; (447 pag.)WO2019/67864; (2019); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

55687-02-0,55687-02-0, 6-Bromo-2-chloroquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

2-chloro-6-bromo quinoxaline (1 .6 g, 6.6 mmol) was dissolved in DMSO (30 mL) at room temperature. (R)-1-(3-chlorophenyl)ethanamine (1.0 g, 6.4 mmol) and TEA (2.75 mL, 9.7 mmol) were added and the reaction mixture was stirred at RT for 18 hours. After completion of the reaction as judged by TLC, water (50 mL) was added to the reaction mixture and the aqueous was extracted with ethyl acetate (25 mL x 3). The organic layer was separated off, washed with water (15mL), brine (15 mL) and was dried over Na2SC>4. The solvent was evaporated off in vacuo at 40C to afford crude title compound. The crude title compound was adsorbed onto silica and was purified by flash column chromatography on silica eluting with a gradient of 0-1 % methanol in DCM to afford the title product (1.28 g, 54%).

The synthetic route of 55687-02-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SENTINEL ONCOLOGY LIMITED; BOYLE, Robert George; WALKER, David Winter; (166 pag.)WO2016/170163; (2016); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.49679-45-0,Ethyl 3-chloroquinoxaline-2-carboxylate,as a common compound, the synthetic route is as follows.,49679-45-0

General procedure: Method A: a solution of compound 3 (1.11 g, 4.70 mmol), 3- aminophenol (622 mg, 5.70 mmol) and p-TSA, as a catalyst, in absolute ethanol (40 mL) was refluxed for 110 h. Ethanol was then evaporated under reduced pressure, and the resulting residue was purified by silica column chromatography using cyclohexane with ethyl acetate gradient (0e50%) as eluent to give the desired compound 4a (1.0 g, 69%) as a red powder.

As the paragraph descriping shows that 49679-45-0 is playing an increasingly important role.

Reference£º
Article; Oyallon, Bruno; Brachet-Botineau, Marie; Loge, Cedric; Bonnet, Pascal; Souab, Mohamed; Robert, Thomas; Ruchaud, Sandrine; Bach, Stephane; Berthelot, Pascal; Gouilleux, Fabrice; Viaud-Massuard, Marie-Claude; Denevault-Sabourin, Caroline; European Journal of Medicinal Chemistry; vol. 154; (2018); p. 101 – 109;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.55687-02-0,6-Bromo-2-chloroquinoxaline,as a common compound, the synthetic route is as follows.

55687-02-0, Methyl (S)-3-methyl-1-oxo-1-((S)-2-(6-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxalin-2-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-1-yl)butan-2-ylcarbamate In a 10 mL seal tube, methyl (S)-3-methyl-1-oxo-1-((S)-2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-1-yl)butan-2-ylcarbamate (100 mg, 213 mmol, Eq: 1.00), 6-bromo-2-chloroquinoxaline (51.8 mg, 213 mumol, Eq: 1.00) and cesium carbonate (139 mg, 425 mumol, Eq: 2.0) were combined with 1,4 dioxane (2.00 ml) and water (0.4 ml) to give a light brown solution. It was degassed for 10 min and tetrakis(triphenylphosphine)palladium (0) (24.6 mg, 21.3 mumol, Eq: 0.1) was added. The reaction mixture was heated to 80 C. and stirred for 16 h. It was diluted with EtOAc (6 ml), filtered through celite, concentrated in vacuo and purified on a silica gel column (CH2Cl2, 2%, 3%, 5%, 8%, 10% MeOH/CH2Cl2) to afford methyl (S)-1-((S)-2-(5-(6-bromoquinoxalin-2-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate as a solid (100 mg, 85.3%). ESI-LRMS m/e calcd for C26H27BrN6O3 [M+] 551, found 552 [M+H+].

The synthetic route of 55687-02-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Alam, Muzaffar; Berthel, Steven Joseph; Brinkman, John A.; Hawley, Ronald Charles; Li, Hongju; Palmer, Wylie Solang; Pietranico-Cole, Sherrie; Sarabu, Ramakanth; Smith, Mark; So, Sung-Sau; Yi, Lin; Zhai, Yansheng; Zhang, Qiang; Zhao, Shu-Hai; US2012/230951; (2012); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

2379-56-8, 6-Nitroquinoxaline-2,3-dione is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

6-Nitroquinoxaline-2,3-(1H,4H)-dione (12 g, 59.0 mmol), thionylchloride (28.1 g, 236 mmol) and catalytic amount of dimethylformamide (0.86 g, 11.8 mmol) were dissolved in dichloroethane solvent, followed by reflux stirring for 2 hours. Upon completion of the reaction, the solvent was eliminated. The temperature was lowered to 05C. to solidify the product. The resulting solid was filtered, and dried under reduced pressure. As a result, 12.3 g of a target compound was obtained (87% yield). Mass (M+H +): 244.1 1H NMR (300 MHz, DMSO-d6): delta8.31 (d, J=9.15 Hz, 1H), 8.60 (d, J=9.15 Hz, 1H), 8.88 (s, 1H)., 2379-56-8

As the paragraph descriping shows that 2379-56-8 is playing an increasingly important role.

Reference£º
Patent; Dong Wha Pharm. Co., Ltd.; Korea Research Institute of Chemical Technology; Lee, Kwangho; Choi, Gildon; Ali, Imran; Lee, Joo Yun; Lee, Jin Soo; Park, Whui Jung; Kim, Yong Tae; Kim, Seung Hwan; Kim, Jung Hwan; Lim, Jae-Kyung; (250 pag.)US2020/39984; (2020); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

50998-17-9, 6-Bromo quinoxaline (2.0 g, 9.5 mmcl) in toluene (20 mL) was degassed for 30 mm. To thissolution, 1-ethoxy vinyl tributyltin (3.8 g, 10.5 mmol) and bis(triphenylphosphine)palladium dichloride (0.67 g, 0.95 mmol) were added at rt and stirred for 16 hours at 90 C. The reaction mixture was cooled to rt and filtered through celite. After evaporation of the solvent, 6 N HCI solution in water (20 mL) was added and the mixture was stirred for I hour at rt. It was concentrated and neutralized with sat. NaHCO3. The desired product wasextracted with DCM (100 mL), dried over Na2SO4 and concentrated. The crude productwas purified by column chromatography to afford the title compound (brown solid). 1H NMR(400 MHz, DMSO-d6): 6 9.06-9.04 (m, 2H), 8.70 (d, J=2.4 Hz, I H), 8.28 (t, J = 2.8 Hz, I H),8.16 (d, J = 11.6 Hz, IH), 2.97 (5, 3H). LCMS: (Method A) 173 (M+H), Rt. 2.25 mm,99.06% (Max).

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; ASCENEURON S. A.; QUATTROPANI, Anna; KULKARNI, Santosh, S.; GIRI, Awadut, Gajendra; (280 pag.)WO2017/144633; (2017); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.89891-65-6,7-Bromo-2-chloroquinoxaline,as a common compound, the synthetic route is as follows.

89891-65-6, a) 7-bromoquinoxaline-2-amine 7-bromo-2-chloroquinoxaline (1.0 g, 4.13 mmol) and ammonia (7 mL) were added to 1,4-dioxane (7 mL). After reaction under agitation at 70 C for 5 h, the reaction mixture was cooled to rt. Water (10 mL) was added, and EA (30 mL*2) was used for extraction. The organic phases were combined, washed with a saturated saline solution (50 mL), dried with anhydrous sodium sulfate, filtered, and concentrated at reduced pressure to obtain a crude compound. Isolation and purification by column chromatography (silica gel, PE: EA = 3:1 as an eluant) were performed to obtain the targeted compound (500 mg, 54.2% yield, yellow solid). LC-MS (ESI): m/z (M+1) 223.99.

As the paragraph descriping shows that 89891-65-6 is playing an increasingly important role.

Reference£º
Patent; Impact Therapeutics, Inc; CAI, Suixiong; TIAN, Ye Edward; (74 pag.)EP3567041; (2019); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider